Weiss Amir 4

What Happened
Amir Weiss, Chief Accounting Officer of Teva Pharmaceutical Industries Ltd (TEVA), had 16,329 restricted share units (RSUs) vest and convert into ordinary shares on March 4, 2026 (10,679 + 5,650). Those vested RSUs were recorded as exercised/converted (derivative transactions) with a $0.00 cash price. On the same date he was also awarded 11,280 new RSUs (no cash paid) as a grant that will vest over future years.

Key Details

• Transaction date: March 4, 2026; Form 4 filed March 6, 2026 (appears timely).
• Vesting/conversion: 10,679 RSUs (from 2022 grant) + 5,650 RSUs (from 2024 grant) = 16,329 RSUs converted to shares; reported derivative “disposed” amount shows $0.00 (no cash sale).
• New award: 11,280 RSUs granted on March 4, 2026 (recorded as acquisition at $0.00). Per footnotes, these 11,280 RSUs vest 2,820 on each of March 4, 2027–2030.
• Footnotes:
  • F1: Ordinary Shares may be represented by American Depositary Shares (ADS), each currently equal to one ordinary share.
  • F2–F5: RSUs represent contingent rights to one ordinary share (or cash at committee option); detailed vesting schedules provided for 2022, 2024 and 2026 grants.
• Shares owned after the transactions: not provided in the data supplied.

Context
These transactions are compensation-related (vesting and new RSU grant), not open-market purchases or sales. The exercise/conversion entries reflect RSUs vesting and being settled into shares rather than an insider buying or selling stock; the new RSU award vests over multiple years and does not represent immediate transferable stock. Such routine equity-compensation filings are common for executives and do not, by themselves, indicate a buy or sell signal.